Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance

Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance

Background We aimed to estimate the public health impact of booster vaccination against COVID-19 in the UK during an Omicron-predominant period. Research design and methods A dynamic transmission model was developed to compare public health outcomes for actual and alternative UK booster vaccination...

Full description

Bibliographic Details
Main Authors:	Diana Mendes, Ruth Chapman, Elena Aruffo, Peter Gal, Jennifer L. Nguyen, Libby Hamson, Manuela Di Fusco, Carole Czudek, Jingyan Yang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Expert Review of Vaccines
Subjects:	covid-19 covid-19 booster vaccination dynamic transmission model omicron variant (b.1.1.529) public health impact sars-cov-2
Online Access:	http://dx.doi.org/10.1080/14760584.2023.2158816

Similar Items

Hybrid immunity and protection against infection during the Omicron wave in Malta
by: John Paul Cauchi, et al.
Published: (2023-12-01)

The latest Omicron BA.4 and BA.5 lineages are frowning toward COVID‐19 preventive measures: A threat to global public health
by: Md. Rabiul Islam, et al.
Published: (2022-11-01)

Literature Review of Omicron: A Grim Reality Amidst COVID-19
by: Suraj Arora, et al.
Published: (2022-02-01)

Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update
by: Ranjan K. Mohapatra, et al.
Published: (2022-11-01)

Omicron Genetic and Clinical Peculiarities That May Overturn SARS-CoV-2 Pandemic: A Literature Review
by: Giorgio Tiecco, et al.
Published: (2022-02-01)

Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China
by: Xiaofeng He, et al.
Published: (2024-01-01)

Multi-layer SPR biosensor for in-Situ Amplified monitoring of the SARS-CoV-2 omicron (B.1.1.529) variant
by: Tarik Bin Abdul Akib, et al.
Published: (2024-02-01)

Challenges of SARS-CoV-2 Omicron Variant and appropriate countermeasures
by: Wenxia Shao, et al.
Published: (2022-06-01)

Probabilistic Approach to COVID-19 Data Analysis and Forecasting Future Outbreaks Using a Multi-Layer Perceptron Neural Network
by: Riaz Ullah Khan, et al.
Published: (2022-10-01)

BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
by: Michal Herman-Edelstein, et al.
Published: (2022-06-01)

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine
by: David W. Hawman, et al.
Published: (2022-09-01)

BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages
by: Bernd Jahrsdörfer, et al.
Published: (2022-06-01)

Evaluation of Rapid Antigen Detection Kits for Detection of SARS-CoV-2 B.1.1.529
by: Gannon C. K. Mak, et al.
Published: (2022-05-01)

SARS-CoV-2 Omicron (B.1.1.529) Variant: Corticosteroids Treatment/Respiratory Coinfection
by: Zeev Elkoshi
Published: (2022-03-01)

Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant
by: Wenlin Ren, et al.
Published: (2023-04-01)

COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis
by: Maria Elena Flacco, et al.
Published: (2022-11-01)

D-dimers in omicron versus delta: A retrospective analysis
by: Alon H. Shulman, et al.
Published: (2022-11-01)

Isolation and Genomic Characterization of SARS-CoV-2 Omicron Variant Obtained from Human Clinical Specimens
by: Pragya D. Yadav, et al.
Published: (2022-02-01)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
by: Donald J. Alcendor, et al.
Published: (2023-04-01)

COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods
by: Syed Mahfuz Al Hasan, et al.
Published: (2022-07-01)

The Omicron (B.1.1.529) SARS-CoV-2 variant of concern also affects companion animals
by: Lidia Sánchez-Morales, et al.
Published: (2022-08-01)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
by: Dorota Zarębska-Michaluk, et al.
Published: (2022-07-01)

Antibiotics daptomycin interacts with S protein of SARS-CoV-2 to promote cell invasion of omicron (B1.1.529) pseudovirus
by: Xu Cao, et al.
Published: (2024-04-01)

TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
by: Kristin Metzdorf, et al.
Published: (2023-01-01)

Social Simulation Model of the Spread and Prevention of the Omicron SARS-CoV-2 Variant
by: Ya Su, et al.
Published: (2022-11-01)

Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction
by: Masaud Shah, et al.
Published: (2023-03-01)

A comprehensive review on Covid-19 Omicron (B.1.1.529) variant
by: R Manjunath, et al.
Published: (2022-09-01)

Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice
by: Gabriela Toomer, et al.
Published: (2022-11-01)

Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center
by: Ruei-Chang Huang, et al.
Published: (2022-12-01)

Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spike—ACE2 Protein–Protein Interaction from a Chemical Space of Privileged Protein Binders
by: Sung-Ting Chuang, et al.
Published: (2022-08-01)

Dynamics of the interaction between the receptor-binding domain of SARS-CoV-2 Omicron (B.1.1.529) variant and human angiotensin-converting enzyme 2
by: Priya Antony, et al.
Published: (2022-07-01)

Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis
by: Yajuan Zhu, et al.
Published: (2022-08-01)

COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
by: David H. Canaday, et al.
Published: (2022-06-01)

Identifying susceptibility of children and adolescents to the Omicron variant (B.1.1.529)
by: June Young Chun, et al.
Published: (2022-11-01)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
by: Jianyang Liu, et al.
Published: (2023-12-01)

A computational evaluation of structural stability of omicron and delta mutations of SARS-CoV-2 spike proteins and human ACE-2 interactions
by: Kehinde A. Idowu, et al.
Published: (2022-01-01)

Interactive effect of booster vaccination and vitamin D status on antibody production of Omicron variant‐infected adults: A real‐world cohort study
by: Denggao Peng, et al.
Published: (2023-10-01)

Molecular dynamics simulations of the delta and omicron SARS-CoV-2 spike – ACE2 complexes reveal distinct changes between both variants
by: Eileen Socher, et al.
Published: (2022-01-01)

Tracing COVID-19 Trails in Wastewater: A Systematic Review of SARS-CoV-2 Surveillance with Viral Variants
by: Ananda Tiwari, et al.
Published: (2023-03-01)

Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy
by: Ashley Priddey, et al.
Published: (2024-01-01)